David D M Nicholl1,2, Patrick J Hanly1,3,4, Ann A Zalucky1,2, Michelle C Mann1,2, Jennifer M MacRae1,2,5, Marc J Poulin2,4,6,7,8, George B Handley9, Darlene Y Sola1,2, Sofia B Ahmed1,2,5. 1. Department of Medicine, University of Calgary, Calgary, Alberta, Canada. 2. Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada. 3. Sleep Centre, Foothills Medical Centre, Calgary, Alberta, Canada. 4. Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. 5. Alberta Kidney Disease Network, Canada. 6. Department of Physiology and Pharmacology, University of Calgary, Calgary, Alberta, Canada. 7. Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. 8. Faculty of Kinesiology, University of Calgary, Alberta, Canada. 9. Healthy Heart Sleep Company, Calgary, Alberta, Canada.
Abstract
STUDY OBJECTIVES: Obstructive sleep apnea (OSA) is associated with increased cardiovascular risk. The effect of OSA treatment with continuous positive airway pressure (CPAP) on the cardiovascular response to a stressor is unknown. We sought to determine the effect of CPAP therapy on heart rate variability (HRV) and arterial stiffness, at baseline, in response to, and recovery from a physiological stressor, Angiotensin II (AngII), in humans with OSA. METHODS: Twenty-five incident healthy subjects (32% female; 49 ± 2 years) with moderate-severe OSA and nocturnal hypoxia were studied in high-salt balance, a state of maximal renin-angiotensin system (RAS) suppression, before CPAP, and after 4 weeks of effective CPAP therapy (usage > 4 h/night) in a second identical study day. HRV was calculated by spectral power and time domain analysis. Aortic augmentation index (AIx) and carotid-femoral pulse-wave velocity (PWVcf) were measured by applanation tonometry. HRV and arterial stiffness were measured at baseline and in response to AngII challenge (3 ng/ kg/min·30 minutes, 6 ng/kg/min·30 minutes, recovery·30 minutes). The primary outcome was the association between CPAP treatment and HRV and arterial stiffness responses to, and recovery from, AngII challenge. In an exploratory analysis subjects were stratified by sex. RESULTS: CPAP corrected OSA and nocturnal hypoxemia. CPAP treatment was associated with increased sensitivity and delayed recovery from AngII (Δln HF [high frequency; recovery: -0.09 ± 0.19 versus -0.59 ± 0.17 ms2, P = .042; ΔrMSSD [root mean successive differences; recovery: -0.4 ± 2.0 versus -7.2 ± 1.9 ms, P = .001], ΔpNN50 [percentage of normal waves differing ≥ 50 ms compared to the preceding wave; AngII: 1.3 ± 2.3 versus -3.0 ± 2.4%, P = .043; recovery: -0.4 ± 1.4 versus -6.0 ± 1.9%, P = .001], all values pre-CPAP versus post-CPAP treatment). No differences were observed by sex. There was increased AIx sensitivity to AngII after CPAP among men (8.2 ± 1.7 versus 11.9 ± 2.2%, P = .046), but not women (11.4 ± 1.5 versus 11.6 ± 2.1%, P = .4). No change in PWVcf sensitivity was observed in either sex. CONCLUSIONS: CPAP therapy was associated with delayed cardiovagal reactivation after a stressor and down-regulation of the arterial RAS. These findings may have important implications in mitigating cardiovascular risk in both men and women with OSA.
STUDY OBJECTIVES:Obstructive sleep apnea (OSA) is associated with increased cardiovascular risk. The effect of OSA treatment with continuous positive airway pressure (CPAP) on the cardiovascular response to a stressor is unknown. We sought to determine the effect of CPAP therapy on heart rate variability (HRV) and arterial stiffness, at baseline, in response to, and recovery from a physiological stressor, Angiotensin II (AngII), in humans with OSA. METHODS: Twenty-five incident healthy subjects (32% female; 49 ± 2 years) with moderate-severe OSA and nocturnal hypoxia were studied in high-salt balance, a state of maximal renin-angiotensin system (RAS) suppression, before CPAP, and after 4 weeks of effective CPAP therapy (usage > 4 h/night) in a second identical study day. HRV was calculated by spectral power and time domain analysis. Aortic augmentation index (AIx) and carotid-femoral pulse-wave velocity (PWVcf) were measured by applanation tonometry. HRV and arterial stiffness were measured at baseline and in response to AngII challenge (3 ng/ kg/min·30 minutes, 6 ng/kg/min·30 minutes, recovery·30 minutes). The primary outcome was the association between CPAP treatment and HRV and arterial stiffness responses to, and recovery from, AngII challenge. In an exploratory analysis subjects were stratified by sex. RESULTS: CPAP corrected OSA and nocturnal hypoxemia. CPAP treatment was associated with increased sensitivity and delayed recovery from AngII (Δln HF [high frequency; recovery: -0.09 ± 0.19 versus -0.59 ± 0.17 ms2, P = .042; ΔrMSSD [root mean successive differences; recovery: -0.4 ± 2.0 versus -7.2 ± 1.9 ms, P = .001], ΔpNN50 [percentage of normal waves differing ≥ 50 ms compared to the preceding wave; AngII: 1.3 ± 2.3 versus -3.0 ± 2.4%, P = .043; recovery: -0.4 ± 1.4 versus -6.0 ± 1.9%, P = .001], all values pre-CPAP versus post-CPAP treatment). No differences were observed by sex. There was increased AIx sensitivity to AngII after CPAP among men (8.2 ± 1.7 versus 11.9 ± 2.2%, P = .046), but not women (11.4 ± 1.5 versus 11.6 ± 2.1%, P = .4). No change in PWVcf sensitivity was observed in either sex. CONCLUSIONS: CPAP therapy was associated with delayed cardiovagal reactivation after a stressor and down-regulation of the arterial RAS. These findings may have important implications in mitigating cardiovascular risk in both men and women with OSA.
Authors: S Marti; G Sampol; X Muñoz; F Torres; A Roca; P Lloberes; T Sagalés; P Quesada; F Morell Journal: Eur Respir J Date: 2002-12 Impact factor: 16.671
Authors: Mala Chidambaram; John A Duncan; Vesta S Lai; Daniel C Cattran; John S Floras; James W Scholey; Judith A Miller Journal: J Am Soc Nephrol Date: 2002-02 Impact factor: 10.121
Authors: Judith A Miller; David Z Cherney; John A Duncan; Vesta Lai; Kevin D Burns; Christopher R J Kennedy; Joseph Zimpelmann; Wei Gao; Daniel C Cattran; James W Scholey Journal: J Am Soc Nephrol Date: 2006-08-16 Impact factor: 10.121
Authors: Ahmed S Abuzaid; Haitham S Al Ashry; Ayman Elbadawi; Ha Ld; Marwan Saad; Islam Y Elgendy; Akram Elgendy; Ahmed N Mahmoud; Amgad Mentias; Amr Barakat; Chitra Lal Journal: Am J Cardiol Date: 2017-06-01 Impact factor: 2.778
Authors: Francisco Campos-Rodriguez; Miguel A Martinez-Garcia; Ines de la Cruz-Moron; Carmen Almeida-Gonzalez; Pablo Catalan-Serra; Josep M Montserrat Journal: Ann Intern Med Date: 2012-01-17 Impact factor: 25.391
Authors: Stavros I Chrysostomakis; Emmanuel N Simantirakis; Sophia E Schiza; Ioannis K Karalis; Nikolaos C Klapsinos; Nikolaos M Siafakas; Panos E Vardas Journal: Hellenic J Cardiol Date: 2006 Jan-Feb
Authors: Nancy A Collop; W McDowell Anderson; Brian Boehlecke; David Claman; Rochelle Goldberg; Daniel J Gottlieb; David Hudgel; Michael Sateia; Richard Schwab Journal: J Clin Sleep Med Date: 2007-12-15 Impact factor: 4.062
Authors: Hua Qin; Brendan T Keenan; Diego R Mazzotti; Fernando Vaquerizo-Villar; Jan F Kraemer; Niels Wessel; Sergio Tufik; Lia Bittencourt; Peter A Cistulli; Philip de Chazal; Kate Sutherland; Bhajan Singh; Allan I Pack; Ning-Hung Chen; Ingo Fietze; Thorarinn Gislason; Steven Holfinger; Ulysses J Magalang; Thomas Penzel Journal: Sleep Date: 2021-05-14 Impact factor: 5.849
Authors: Mackenzie Green; Gie Ken-Dror; David Fluck; Charif Sada; Pankaj Sharma; Christopher H Fry; Thang S Han Journal: J Clin Hypertens (Greenwich) Date: 2020-09-24 Impact factor: 3.738